Author: Daniel Mediavilla
David Mejía, a 28-year-old battling a rare cancer, sought treatment from Immucura Med S.L in hopes of finding a cure. Despite traveling between different clinics and countries, he tragically passed away at the age of 29. The founder of Immucura, Johannes Schumacher, faces accusations of fraud and health violations, where the company provided illegal therapies to cancer patients. The investigation into Immucura’s activities revealed a shadowy network of clinics and laboratories across Europe. The company promised cutting-edge treatments using dendritic cells, but lacked proper authorization and medical expertise. Patients were lured by the hope of innovative therapies, raising funds through…
In 2023, Chris Booth — the director of the Division of Cancer Care and Epidemiology at Queen’s Cancer Research Institute (QCRI) — and other oncologists worldwide initiated the Common Sense Oncology project to spark public debate about concerning trends in oncology. Many cancer treatments offer limited benefits at a high cost and with significant toxicity, keeping patients in hospitals for extended periods near the end of their lives. In his studies, Booth highlights that current treatments often fall short of standard efficacy thresholds, focusing on factors like tumor growth inhibition rather than overall survival rates. The Common Sense Oncology initiative…